Resistance to Osimertinib to create a Flurry of Activity To Find Out Why in 2018

Resistance to Osimertinib to create a Flurry of Activity To Find Out Why in 2018

thoraciconcology

2 years
293 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Roy S. Herbst, MD, PhD of Yale Cancer Center talks about possible flurry of activity that focuses on resistance to osimertinib in 2018. Dr. Herbst highlights the lack of any therapy that specifically targets the resistance. Patients who are doing well with the EGFR inhibitors can only have chemotherapy and not any specialized therapy because of this problem. Hence, he highly anticipated that next year will have more activities, specifically on developing some strategies, perhaps the combination of antibodies, plus small molecules and immunotherapy and other approach that could better help target resistance.
Up Next Autoplay